Pramipexole ER vs IR PK in Japanese Healthy Males

Phase 1, randomised, open-label trial of pramipexole in Parkinson's disease (PD) and restless legs syndrome (RLS) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state over 24 hours for ER at Day 5 and Area under the concentration-time curve at steady state over 24 hours for IR. Started Sep 2006; status: completed.